These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 14614678)

  • 1. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy.
    Tarwater PM; Parish M; Gallant JE
    Clin Infect Dis; 2003 Dec; 37(11):1541-8. PubMed ID: 14614678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3.
    Fillaux J; Delpierre C; Alvarez M; Jaafar A; Marchou B; Massip P; Cuzin L
    Med Mal Infect; 2006 Jun; 36(6):335-9. PubMed ID: 16631330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
    Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M
    AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection.
    Boschi A; Tinelli C; Ortolani P; Arlotti M
    J Antimicrob Chemother; 2006 Mar; 57(3):520-6. PubMed ID: 16387747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
    Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
    AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment.
    David D; Naït-Ighil L; Dupont B; Maral J; Gachot B; Thèze J
    J Infect Dis; 2001 Mar; 183(5):730-5. PubMed ID: 11181149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR; Chaisson RE; Keruly J; Moore RD
    J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.